French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.

Legal & General Assurance Society Limited (“Legal & General”) has completed a £1.4 billion buy-in with the Sanofi Pension Scheme (“the Scheme”), securing the benefits of 4,900 retirees and 5,600 ...

Sanofi Pension Scheme has completed a £1.4bn (€1.7bn) buy-in securing the benefits of 4,900 retirees and 5,600 deferred ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 ...

Sir Jonathan Van-Tam will work across the Health & Life Sciences client portfolio as it grows Sir Jonathan previously served as Deputy Chief Medical Officer to HM Government from 2017 to 2022 and was ...

The Company and Rhone-Poulenc Rorer (India) Ltd. two separate Indian subsidiaries of the French Pharmaceuticals and Chemicals major, Aventis SA, are implementing employee stock option schemes as ...

We thank our colleagues for their interest in our Article.1 In response to Ari R Joffe, we provided estimates of the number of severe outcomes associated with a fully vaccinated counterfactual. These ...

Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The defendants listed include the drug manufacturers Eli Lilly, Novo Nordisk and Sanofi Aventis U.S., and PBM ... are the key counterweight to pharmaceutical companies' otherwise unchecked ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...